Cardio Diagnostics Holdings annual stock-based compensation
2021
2022
2023
2024
2025
Cardio Diagnostics Holdings Stock-Based Compensation Growth & History (CDIO)
Cardio Diagnostics Holdings's stock-based compensation was $110,235 for fiscal 2025.
View full Cardio Diagnostics Holdings company overviewCardio Diagnostics Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $110,235 | −$2.5M | −95.75% |
| 2024 | 2024-12-31 | $2.6M | $1.3M | +102.55% |
| 2023 | 2023-12-31 | $1.3M | $1.3M | — |
| 2022 | 2022-12-31 | $0 | −$60,000 | — |
| 2021 | 2021-12-31 | $60,000 | — | — |
Cardio Diagnostics Holdings quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $24,352 | −$6,426 | −20.88% |
| Q1 2026 | 2026-03-31 | $24,733 | −$5,879 | −19.20% |
| Q4 2025 | 2025-12-31 | $24,083 | $1,668 | +7.44% |
| Q3 2025 | 2025-09-30 | $24,762 | $2,144 | +9.48% |
| Q2 2025 | 2025-06-30 | $30,778 | $4,047 | +15.14% |
| Q1 2025 | 2025-03-31 | $30,612 | −$2.5M | −98.78% |
| Q4 2024 | 2024-12-31 | $22,415 | −$39,585 | −63.85% |
| Q3 2024 | 2024-09-30 | $22,618 | −$49,382 | −68.59% |
| Q2 2024 | 2024-06-30 | $26,731 | −$1.1M | −97.66% |
| Q1 2024 | 2024-03-31 | $2.5M | $2.5M | +62885.10% |
| Q4 2023 | 2023-12-31 | $62,000 | $62,000 | — |
| Q3 2023 | 2023-09-30 | $72,000 | $72,000 | — |
| Q2 2023 | 2023-06-30 | $1.1M | $1.1M | — |
| Q1 2023 | 2023-03-31 | $4,000 | $4,000 | — |
| Q4 2022 | 2022-12-31 | $0 | — | — |
| Q3 2022 | 2022-09-30 | $0 | — | — |
| Q2 2022 | 2022-06-30 | $0 | — | — |
| Q1 2022 | 2022-03-31 | $0 | — | — |
Cardio Diagnostics Holdings stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Cardio Diagnostics Holdings's stock-based compensation increased from $60,000 to $110,235, a change of $50,235. The latest reported quarter, Q2 2026, shows $24,352.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardio Diagnostics Holdings source filings ↗